Asgard Therapeutics Has an EIC Accelerator Shot at Dendritic Cells

17 November 20261,833 words10 min

Dendritic cells are the immune system's informers: they pick up fragments of what is wrong in the body and show them to T cells, which then go to work. Solid tumours survive in part by keeping those informers out. Asgard Therapeutics, a company registered in Lund in December 2018, proposes to manufacture them inside the tumour instead, by injecting a virus that reprograms cancer cells themselves into dendritic cells. On 16 November 2026 the European Innovation Council named it among 35 companies selected for Accelerator support.

The project is called Tumor2DC and the published list describes it as "in vivo reprogramming with AT-108, a novel off-the-shelf and personalized cancer immunotherapy", recommended for blended finance. The EIC states in the same document that selection "does not constitute a formal commitment for funding" and that final decisions follow grant preparation. That matters here, because almost everything verifiable about Asgard today predates the award.

€30MSeries A closed in March 2024, per the company
35 of 453Companies selected from the full applications in this round
0Clinical trials of AT-108 registered or announced in sources reviewed on 17 November 2026

Company file

Legal entity
Asgard Therapeutics AB, organisation number 559184-0136, registered 6 December 2018
Headquarters
Medicon Village, Lund, Sweden
Origin
Research started in 2015 at the University of Coimbra and moved to Lund University in 2017, per the company
Chief executive
Cristiana Pires, co-founder, listed as external CEO in the register
Other co-founders
Fábio Rosa, VP of Research, and Filipe Pereira, Head of Innovation
Chair
Martin Bonde
Investors
Novo Holdings, Boehringer Ingelheim Venture Fund, Industrifonden, RV Invest, Johnson & Johnson Innovation JJDC
Earlier EU projects
TrojanDC, SME Instrument phase 1, €50,000, 2019 to 2020; TrojanDC, Women TechEU, €75,000, 2023 to 2024
Staff
13 employees in the accounts for 2025

Turning the tumour into its own accuser

The mechanism is specific enough to be checked. A replication-deficient adenoviral vector is injected into the tumour and delivers three transcription factors, PU.1, IRF8 and BATF3, into cancer cells. Those three factors push the cell towards the fate of a type 1 conventional dendritic cell, which presents the tumour's own antigens to T cells. Because the reprogrammed cell was the tumour, the antigens are the patient's; because the product is a fixed vector rather than cells grown per patient, the company calls it off-the-shelf and personalised at the same time.

The work is published rather than asserted. Ascic et al., Science, 2024 reported in vivo dendritic cell reprogramming for cancer immunotherapy, the proof-of-concept study behind AT-108. In November 2026 the company announced a second paper in Immunity, with Lund University, the Shanghai Cancer Centre and the University of Coimbra, reporting that reprogramming induced mature immunogenic tertiary lymphoid structures in seven mouse tumour models, that B cells were required for both those structures and tumour control, and that complete response rates rose against anti-PD1 treatment alone. All of it is preclinical, and the company says so.

What the company published, and what it claims

The published results are in mice and in human tumour samples examined after the fact. The two indications Asgard has named for a first trial, microsatellite stable colorectal cancer and PD-L1-negative head and neck squamous cell carcinoma, are groups that respond poorly to checkpoint inhibitors, which is the commercial argument. Neither indication has been tested in a patient with AT-108: the company's own reporting to the Commission describes the trial as designed, not run.

The record

Eleven years from a Coimbra laboratory to an EIC Accelerator selection

Every entry below is dated by a company statement, a CORDIS fact sheet, the Swedish register or a journal publication. The clinical steps are still ahead of the company.

  1. 2015Research beginsThe scientific founders start work on dendritic cell reprogramming at the University of Coimbra, per the company
  2. Dec 2018Company registeredAsgard Therapeutics AB is registered in Sweden on 6 December 2018, organisation number 559184-0136
  3. Dec 2019First EU grantSME Instrument phase 1 project TrojanDC runs to May 2020 with an EU contribution of €50,000€50,000
  4. Oct 2021Seed roundA €6M seed round co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, per the company€6M
  5. Jul 2023Women TechEU grantA €75,000 Horizon Europe grant to write the roadmap for IND-enabling studies and a first-in-human trial€75,000
  6. Mar 2024Series AA €30M round co-led by RV Invest and Johnson & Johnson Innovation, JJDC, Inc.€30M
  7. Sep 2024Science paperIn vivo dendritic cell reprogramming for cancer immunotherapy is published in Science
  8. Nov 2026Immunity paperReprogramming induces immunogenic lymphoid structures across seven tumour models, with an AT-108 biomarker poster at SITC
  9. Nov 2026EIC selectionOne of 35 companies selected from the May to July 2026 cut-offs, for blended financeTumor2DC

Swedish company register via Allabolag; CORDIS, TrojanDC 882918 and 101113889; Asgard Therapeutics news and About page; Science, 2024; Immunity, 2026; EIC, 16 November 2026.

A company that was already funded

Asgard reached the EIC Accelerator with money in the bank. It announced a €6 million seed round in October 2021 co-led by Novo Holdings, the Boehringer Ingelheim Venture Fund and Industrifonden, and on 14 March 2024 a €30 million Series A co-led by RV Invest and Johnson & Johnson Innovation, JJDC, Inc., with the seed investors taking part. Novo Holdings said the money would advance the platform towards the clinic, expand the research team and fund new reprogramming and delivery approaches, and that Asgard planned to reach readiness to file an investigational new drug application for its lead programme by 2026.

The Swedish register shows what that looks like in filed figures. The accounts for the year to 31 December 2025, summarised by Allabolag, report revenue of SEK 8.9 million, a result after financial items of minus SEK 76.0 million, equity of SEK 200.2 million against total assets of SEK 231.5 million, and 13 employees. A loss of that size is what a preclinical gene therapy programme costs rather than a sign of trouble, and the equity ratio Allabolag gives for 2024, 92.5%, shows a balance sheet carried by share capital rather than debt. No turnover from product sales is reported, and none would be expected.

Public money came earlier and in small amounts. CORDIS records an SME Instrument phase 1 project, also called TrojanDC, from December 2019 to May 2020 with an EU contribution of €50,000 against total costs of €71,429. A second CORDIS entry, grant 101113889, records a €75,000 Women TechEU grant from July 2023 to June 2024, whose purpose was to produce the roadmap for IND-enabling studies and a first-in-human trial, a business plan for the Series A, and investor contacts. The company also lists a €2 million Eurostars award from October 2021, shared with Lund University, InSphero and Antineo, and Swedish grants from Vinnova and SWElife.

The money

The EIC grant ceiling is a twelfth of the round Asgard closed in 2024

The grant ceiling is the EIC's published maximum for the Accelerator, not an amount confirmed for this company: no figure for Tumor2DC has been published. The seed and Series A figures are the company's own, and the Eurostars award covered a four-partner consortium.

Asgard Therapeutics About page and Series A release, 14 March 2024; CORDIS, TrojanDC 882918 and 101113889; EIC, 16 November 2026. Values in € millions.

What the November 2026 round actually says

The EIC's announcement gives the shape of the cohort: 453 full applications, 88 interviews and 35 companies selected, drawn from 17 EU and associated countries, with €84 million of grants proposed in total and 32 of the 35 to be assessed by the EIC Fund for equity of up to €10 million each. A further 74 applications above threshold but unfunded receive a Seal of Excellence, and 13 companies a STEP Seal. The EIC says grant agreements are expected to be finalised within three months, which is why there is no Tumor2DC project in CORDIS: searches of CORDIS on 17 November 2026 return only the two earlier TrojanDC projects.

One figure in the announcement is worth holding against this company: 31% of the selected companies are led by women in a role such as CEO, CTO or CSO. Asgard is one of them, and it has been inside the EU's programmes for women-led deep tech before, having been named in April 2023 as one of 467 recipients of a Women TechEU grant. No amount for Tumor2DC has been published, and no EIC Fund investment in Asgard appears on the EIC Fund's portfolio pages reviewed on 17 November 2026.

The competition

35 selected from 453 full applications

The EIC says 32 of the 35 selected companies will be assessed by the EIC Fund for equity of up to €10 million each, and that the grants proposed to the group total €84 million.

EIC, The European Innovation Council selects 35 deep tech companies for its Accelerator support, 16 November 2026.

The promise, and what can be checked today

  1. Reprogramming works in vivoPublishedProof of concept in Science, 2024, and across seven tumour models in Immunity, 2026, both in mice.
  2. Intellectual property securedGrantedEuropean patent EP3607055B1 on reprogramming cells into dendritic cells, granted 14 May 2025 to Asgard Therapeutics AB, with anticipated expiry in April 2038.
  3. Roadmap to a first-in-human trialDeliveredThe final report of the Women TechEU project records a chosen manufacturer, planned toxicology and biodistribution studies, a five-dose Phase I design and two priority indications.
  4. IND readiness by 2026Not publicNo filing or clearance has been announced by the company; its release of 4 November 2026 says it aims to take AT-108 towards the clinic next year.
  5. Patient dataNone yetSources reviewed on 17 November 2026 show no registered or announced clinical trial of AT-108.
  6. Tumor2DC grant agreementToo earlySelected on 16 November 2026; the EIC expects agreements to be finalised within three months, and CORDIS lists no project.

What the company says

A first-in-class, off-the-shelf gene therapy that converts tumour cells into dendritic cells, validated across seven tumour types, with a platform that also screens transcription factor combinations for other immune cell fates.

What the record shows

Three papers in Science, Immunity and Cell Systems, one granted European patent, two closed EU projects worth €125,000 in total, an announced €6 million seed round and an announced €30 million Series A, 13 employees, and no trial in a human being.

Why Brussels is interested

The policy fit is close. The Commission's life sciences strategy of 2 July 2025 sets out to make Europe the most attractive place for life sciences by 2030, and the European Biotech Act, proposed in December 2025, names easier access to funding for start-ups and SMEs among its aims. Advanced therapies are also where European companies have repeatedly handed the clinical and commercial stage to American buyers, and Asgard's board already seats two corporate investors, Boehringer Ingelheim and Johnson & Johnson, through their venture arms. Whether a European grant of at most €2.5 million changes who eventually owns this therapy is not something the selection document answers.

Verdict

Asgard Therapeutics is the kind of applicant the Accelerator was designed for and the kind whose risk is hardest to price: a published mechanism, a granted patent, blue-chip pharmaceutical investors, and a product that has never met a patient. The grant arrives after the venture money rather than before it, which is a reasonable use of a deep-tech instrument if the money buys the step from a designed trial to an open one. On 17 November 2026 that step has not been taken, and the company's own target of readiness to file by 2026 has not been reported as met.

The reporting is based on publicly available sources, listed below.

Industry

HealthBiopharmaceuticals

Focus
  • Gene therapies
Technologies
  • Viral vectors
  • Cell engineering
  • Immunotherapy
Keywords
  • Oncology
  • Solid tumours
  • Colorectal cancer
  • Head and neck cancer
  • Dendritic cells